CNTA CENTESSA PHARMACEUTICALS PLC US FDA Inspections 8-K Filing 2023 - FDA Clearance of IND Application for Phase 1/2a Clinical Trial of LB101 for Solid Tumors Centessa Pharmaceuticals announces FDA clearance of IND application for Phase 1/2a clinical trial of LB101, a LockBody candidate for solid tumors.Get access to all SEC 8-K filings of the CENTESSA PHARMACEUTICALS PLC